Thursday, March 28, 2019

Dyadic International (DYAI)

Could 2019 be transformational?

Dyadic International Inc. is a biotechnology company developing a proprietary expression platform to manufacture of biologic products. The company is employing C1 technology, part of a fungi expression system, to produce variety of modalities of biologic products, including vaccines, oncolytic viruses, monoclonal and bispecific antibodies, as well as biosimilars. 

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.  

• R&D
  Advancement. The company continues to make progression in
  establishing C1 expression production and the purification process in multiple
  projects. The Schmallenberg virus (SBV) as part of the ZAPI project exceeded
  the intended expression levels (17x), and is potentially the first to enter in
  human trials. We believe glycan engineering intended in 2019 could be
  transformational for the company.
• Corporate
  Updates. The proof of concept collaborations totaled nine projects,
  including two newly added agreements with large pharmaceuticals in Q1 2019.
  Dyadic continues to validate C1’s potential in biologic manufacturing, guiding
  an $8-$10 million burn rate this year. However, business development efforts
  are ongo… 

Get full report on Channelchek desktop.

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.